$359.2M in CY2024 Part D spend49K claims · 10K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Golimumab used for?
Golimumab suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.
Is there a generic for Golimumab?
No. Golimumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Golimumab?
Across 329 Part D plans, Golimumab averages $12975.88/unit (NADAC). Lowest available: $12974.52/unit. Highest in distribution: $12977.24/unit.
Is Golimumab on the FDA shortage list?
No. Golimumab is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.